{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:37:10Z","timestamp":1790764630288,"version":"4.1.0"},"reference-count":53,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The main treatments for patients with nonalcoholic fatty liver disease (NAFLD) are currently based on lifestyle changes, including ponderal decrease and dietary management. However, a subgroup of patients with nonalcoholic steatohepatitis (NASH), who are unable to modify their lifestyle successfully, may benefit from pharmaceutical support. Several drugs targeting pathogenic mechanisms of NAFLD have been evaluated in clinical trials for the treatment of NASH. Farnesoid X receptor (FXR) is a nuclear key regulator controlling several processes of the hepatic metabolism. NAFLD has been proven to be associated with abnormal FXR activity. Obeticholic acid (OCA) is a first-in-class selective FXR agonist with anticholestatic and hepato-protective properties. Currently, OCA is registered for the treatment of primary biliary cholangitis. However, promising effects of OCA on NASH and its metabolic features have been reported in several studies.<\/jats:p>","DOI":"10.3390\/ph11040104","type":"journal-article","created":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T02:58:04Z","timestamp":1539313084000},"page":"104","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5922-1524","authenticated-orcid":false,"given":"Ludovico","family":"Abenavoli","sequence":"first","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d, Viale Europa-Germaneto, 8810 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetyana","family":"Falalyeyeva","sequence":"additional","affiliation":[{"name":"School of Medicine, Taras Shevchenko National University of Kyiv, Volodymyrska Street 64\/13, 01601 Kiev, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Boccuto","sequence":"additional","affiliation":[{"name":"Greenwood Genetic Center, Greenwood, SC 29646, USA"},{"name":"School of Health Research, Clemson University, Clemson, SC 29646, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena","family":"Tsyryuk","sequence":"additional","affiliation":[{"name":"School of Medicine, Taras Shevchenko National University of Kyiv, Volodymyrska Street 64\/13, 01601 Kiev, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9814-689X","authenticated-orcid":false,"given":"Nazarii","family":"Kobyliak","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Bogomolets National Medical University, Pushkinska 22a, 01610 Kiev, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,10,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/cld.81","article-title":"Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup","volume":"1","author":"Puri","year":"2012","journal-title":"Clin. Liver Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.dld.2010.01.021","article-title":"Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee","volume":"42","author":"Loria","year":"2010","journal-title":"Dig. Liver Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/1574887109666141216102231","article-title":"The role of liver biopsy to assess non-alcoholic fatty liver disease","volume":"9","author":"Kobyliak","year":"2014","journal-title":"Rev. Recent Clin. Trials"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40200-015-0170-1","article-title":"Diagnostic accuracy of acyl-ghrelin and it association with non-alcoholic fatty liver disease in type 2 diabetic patients","volume":"14","author":"Mykhalchyshyn","year":"2015","journal-title":"J. Diabetes Metab. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.3748\/wjg.v22.i31.7006","article-title":"Metabolic aspects of adult patients with nonalcoholic fatty liver disease","volume":"22","author":"Abenavoli","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Abenavoli, L., Greco, M., Milic, N., Accattato, F., Foti, D., Gulletta, E., and Luzza, F. (2017). Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study. Nutrients, 9.","DOI":"10.3390\/nu9080870"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","article-title":"Fructose and sugar: A major mediator of non-alcoholic fatty liver disease","volume":"68","author":"Jensen","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome","volume":"2","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.diabres.2018.05.005","article-title":"Probiotics and nutraceuticals as a new frontier in obesity prevention and management","volume":"141","author":"Kobyliak","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12602-016-9230-1","article-title":"Probiotics supplemented with omega-3 fatty acids are more effective for hepatic steatosis reduction in an animal model of obesity","volume":"9","author":"Kobyliak","year":"2017","journal-title":"Probiotics Antimicrob. Proteins"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kobyliak, N., Abenavoli, L., Falalyeyeva, T., Mykhalchyshyn, G., Boccuto, L., Kononenko, L., Kyriienko, D., Komisarenko, I., and Dynnyk, O. (2018). Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: A randomized clinical study. Minerva Med.","DOI":"10.23736\/S0026-4806.18.05845-7"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1586\/17474124.2015.1004312","article-title":"Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease","volume":"9","author":"Abenavoli","year":"2015","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kobyliak, N., Falalyeyeva, T., Virchenko, O., Mykhalchyshyn, G., Bodnar, P., Spivak, M., Yankovsky, D., Beregova, T., and Ostapchenko, L. (2016). Comparative experimental investigation on the efficacy of mono- and multiprobiotic strains in non-alcoholic fatty liver disease prevention. BMC Gastroenterol., 16.","DOI":"10.1186\/s12876-016-0451-2"},{"key":"ref_20","first-page":"659","article-title":"Probiotics for experimental obesity prevention: Focus on strain dependence and viability of composition","volume":"68","author":"Kobyliak","year":"2017","journal-title":"Endokrynol. Pol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5604\/01.3001.0010.7547","article-title":"Efficacy of Probiotics and Smectite in Rats with Non-Alcoholic Fatty Liver Disease","volume":"17","author":"Kobyliak","year":"2018","journal-title":"Ann. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.15403\/jgld.2014.1121.271.kby","article-title":"A Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in NAFLD Patients: Evidence from a Randomized Clinical Trial","volume":"27","author":"Kobyliak","year":"2018","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2217\/pme.14.44","article-title":"Personalizing care for nonalcoholic fatty liver disease patients: What are the research priorities?","volume":"11","author":"Sookoian","year":"2014","journal-title":"Per. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-981-10-8684-7_12","article-title":"Current Prevention and Treatment Options for NAFLD","volume":"1061","author":"Wong","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Yu, Q., Jiang, Z., and Zhang, L. (2018). Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease. Pharmacol. Ther.","DOI":"10.1016\/j.pharmthera.2018.04.005"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.tem.2017.11.002","article-title":"Role of Bile Acids in Metabolic Control","volume":"29","author":"Molinaro","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6\u03b1-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1021\/jm049904b","article-title":"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid","volume":"47","author":"Pellicciari","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2147\/TCRM.S113052","article-title":"New developments in the treatment of primary biliary cholangitis\u2014Role of obeticholic acid","volume":"13","author":"Jhaveri","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jhep.2012.08.002","article-title":"Bile acid transporters and regulatory nuclear receptors in the liver and beyond","volume":"58","author":"Halilbasic","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1101\/gad.1083503","article-title":"Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis","volume":"17","author":"Holt","year":"2003","journal-title":"Genes Dev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/MOG.0b013e32834452c8","article-title":"Farnesoid X receptor agonists for primary biliary cirrhosis","volume":"27","author":"Lindor","year":"2011","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MOG.0000000000000058","article-title":"Primary biliary cirrhosis in 2014","volume":"30","author":"Flores","year":"2014","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.drudis.2012.05.012","article-title":"Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis","volume":"17","author":"Adorini","year":"2012","journal-title":"Drug Discov. Today"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1194\/jlr.M001602","article-title":"FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa\/fa) obese rats","volume":"51","author":"Cipriani","year":"2010","journal-title":"J. Lipid Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1152\/ajpheart.01075.2008","article-title":"Antiatherosclerotic effect of farnesoid X receptor","volume":"296","author":"Mencarelli","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.bbadis.2014.02.004","article-title":"FXR-dependent reduction of hepatic steatosis in a bile salt deficient mouse model","volume":"1842","author":"Kunne","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/oby.21701","article-title":"Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice","volume":"25","author":"Haczeyni","year":"2017","journal-title":"Obesity"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.22519","article-title":"Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response","volume":"48","author":"Wang","year":"2008","journal-title":"Hepatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1124\/mol.117.111047","article-title":"Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-\u03baB Signaling, and Hepatic Inflammation","volume":"94","author":"Gai","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1161\/ATVBAHA.107.152694","article-title":"Farnesoid X receptor ligands inhibit vascular smooth muscle cell inflammation and migration","volume":"27","author":"Li","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e003995","DOI":"10.1136\/bmjopen-2013-003995","article-title":"Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): Study protocol for a phase II multicentre, double-blinded, randomised, controlled trial","volume":"3","author":"Armstrong","year":"2013","journal-title":"BMJ Open"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-\u03b1 and -\u03b4, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","article-title":"Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis","volume":"24","author":"Kristiansen","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.2353\/ajpath.2009.090114","article-title":"Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts","volume":"175","author":"Fickert","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXRand protects againstliver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_49","first-page":"1040A","article-title":"Anti-fibrotic activity of INT-747, a novel FXR activator, in vitro and in experimental liver fibrosis and cirrhosis","volume":"42","author":"Albanis","year":"2005","journal-title":"Hepatology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8157","DOI":"10.1038\/s41598-018-26383-8","article-title":"Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis","volume":"25","author":"Goto","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial","volume":"385","author":"Loomba","year":"2015","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/apt.14492","article-title":"NASH CRN. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis","volume":"47","author":"Hameed","year":"2018","journal-title":"Aliment. Pharmacol. Ther."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/11\/4\/104\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:25:05Z","timestamp":1760196305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/11\/4\/104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,11]]},"references-count":53,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["ph11040104"],"URL":"https:\/\/doi.org\/10.3390\/ph11040104","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,11]]}}}